Dual-hormone Artificial Pancreas for Glucose Control in Type 1 Diabetes: A Meta-analysis

Overview

Journal Diabetes Obes Metab

Specialty Endocrinology

Date 2022 May 31

PMID 35638377

Authors

Baoqi Zeng

Hao Jia

Le Gao

Qingqing Yang

Kai Yu

Feng Sun

Affiliations

Soon will be listed here.

Abstract

Aim: To evaluate the efficacy and safety of a dual-hormone artificial pancreas (DH) in type 1 diabetes.

Material And Methods: PubMed, Embase, the Cochrane Library and ClinicalTrials.gov were searched for studies published up to February 16, 2022. We included randomized controlled trials that compared DH with single-hormone artificial pancreas (SH), continuous subcutaneous insulin infusion (CSII) or sensor-augmented pumps (SAP), and predictive low glucose suspend systems (PLGS) in type 1 diabetes. The primary outcome was percent time in target (3.9-10 mmol/L [70-180 mg/dL]). Data were summarized as mean differences (MDs) or risk differences (RDs).

Results: A total of 17 randomized crossover trials (438 participants) were included. There were nine trials of DH versus SH, 13 trials of DH versus SAP/CSII, and two trials of DH versus PLGS. For time in target, DH showed no significant difference in time in target compared with SH (MD 2.69%, 95% confidence interval [CI] -0.38 to 5.76) but resulted in 16.05% (95% CI 12.06 to 20.05) and 6.89% (95% CI 2.63 to 11.14) more time in target range compared with SAP/CSII and PLGS, respectively. DH slightly reduced time in hypoglycaemia (MD -1.20%, 95% CI -1.85 to -0.56) but increased the risk of gastrointestinal symptoms (RD 0.18, 95% CI 0.08 to 0.27) compared with SH.

Conclusions: The results of this study suggest that DH has a comparable effect on time in target compared with SH, but is associated with a longer time in target range compared with SAP/CSII and PLGS. The DH slightly reduced time in hypoglycaemia but may increase the risk of gastrointestinal symptoms compared with the SH. PROSPERO registration number: CRD42022314015.

Citing Articles

Automating insulin delivery through pump and continuous glucose monitoring connectivity: Maximizing opportunities to improve outcomes.

Anandhakrishnan A, Hussain S Diabetes Obes Metab. 2024; 26 Suppl 7:27-46.

PMID: 39291355 PMC: 11864493. DOI: 10.1111/dom.15920.

Automated blood glucose regulation for nonlinear model of type-1 diabetic patient under uncertainties: GWOCS type-2 fuzzy approach.

Elhoushy M, Zalam B, Sayed A, Nabil E Biomed Eng Lett. 2024; 14(1):127-151.

PMID: 38186949 PMC: 10769999. DOI: 10.1007/s13534-023-00318-3.

Efficacy of automated insulin delivery (AID) systems in type 1 diabetes: protocol of a systematic review and network meta-analysis of outpatient randomised controlled trials.

Stahl-Pehe A, Schlesinger S, Kuss O, Shokri-Mashhadi N, Bachle C, Warz K BMJ Open. 2023; 13(10):e074317.

PMID: 37816564 PMC: 10565260. DOI: 10.1136/bmjopen-2023-074317.

Intelligent Insulin vs. Artificial Intelligence for Type 1 Diabetes: Will the Real Winner Please Stand Up?.

Cambuli V, Baroni M Int J Mol Sci. 2023; 24(17).

PMID: 37685946 PMC: 10488097. DOI: 10.3390/ijms241713139.

Dual hormone fully closed loop in type 1 diabetes: a randomised trial in the Netherlands - study protocol.

Jancev M, Snoek F, Frederix G, Knottnerus H, Blauw H, Witkop M BMJ Open. 2023; 13(8):e074984.

PMID: 37612114 PMC: 10450048. DOI: 10.1136/bmjopen-2023-074984.

References

Russell S, Hillard M, Balliro C, Magyar K, Selagamsetty R, Sinha M . Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial. Lancet Diabetes Endocrinol. 2016; 4(3):233-243. PMC: 4799495. DOI: 10.1016/S2213-8587(15)00489-1. View

Eckstein M, Weilguni B, Tauschmann M, Zimmer R, Aziz F, Sourij H . Time in Range for Closed-Loop Systems versus Standard of Care during Physical Exercise in People with Type 1 Diabetes: A Systematic Review and Meta-Analysis. J Clin Med. 2021; 10(11). PMC: 8198013. DOI: 10.3390/jcm10112445. View

Miller K, Foster N, Beck R, Bergenstal R, DuBose S, DiMeglio L . Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care. 2015; 38(6):971-8. DOI: 10.2337/dc15-0078. View

Haidar A, Tsoukas M, Bernier-Twardy S, Yale J, Rutkowski J, Bossy A . A Novel Dual-Hormone Insulin-and-Pramlintide Artificial Pancreas for Type 1 Diabetes: A Randomized Controlled Crossover Trial. Diabetes Care. 2020; 43(3):597-606. DOI: 10.2337/dc19-1922. View

Zeng B, Jia H, Gao L, Yang Q, Yu K, Sun F . Dual-hormone artificial pancreas for glucose control in type 1 diabetes: A meta-analysis. Diabetes Obes Metab. 2022; 24(10):1967-1975. PMC: 9542047. DOI: 10.1111/dom.14781. View

Blauw H, van Bon A, Koops R, DeVries J . Performance and safety of an integrated bihormonal artificial pancreas for fully automated glucose control at home. Diabetes Obes Metab. 2016; 18(7):671-7. PMC: 5111773. DOI: 10.1111/dom.12663. View

Higgins J, Altman D, Gotzsche P, Juni P, Moher D, Oxman A . The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343:d5928. PMC: 3196245. DOI: 10.1136/bmj.d5928. View

Jacobs P, El Youssef J, Reddy R, Resalat N, Branigan D, Condon J . Randomized trial of a dual-hormone artificial pancreas with dosing adjustment during exercise compared with no adjustment and sensor-augmented pump therapy. Diabetes Obes Metab. 2016; 18(11):1110-1119. PMC: 5056819. DOI: 10.1111/dom.12707. View

Russell S, El-Khatib F, Sinha M, Magyar K, McKeon K, Goergen L . Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N Engl J Med. 2014; 371(4):313-325. PMC: 4183762. DOI: 10.1056/NEJMoa1314474. View

10.

Abitbol A, Rabasa-Lhoret R, Messier V, Legault L, Smaoui M, Cohen N . Overnight Glucose Control with Dual- and Single-Hormone Artificial Pancreas in Type 1 Diabetes with Hypoglycemia Unawareness: A Randomized Controlled Trial. Diabetes Technol Ther. 2018; 20(3):189-196. DOI: 10.1089/dia.2017.0353. View

11.

Fullerton B, Jeitler K, Seitz M, Horvath K, Berghold A, Siebenhofer A . Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2014; (2):CD009122. PMC: 6486147. DOI: 10.1002/14651858.CD009122.pub2. View

12.

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

13.

Wilson L, Jacobs P, Ramsey K, Resalat N, Reddy R, Branigan D . Dual-Hormone Closed-Loop System Using a Liquid Stable Glucagon Formulation Versus Insulin-Only Closed-Loop System Compared With a Predictive Low Glucose Suspend System: An Open-Label, Outpatient, Single-Center, Crossover, Randomized Controlled Trial. Diabetes Care. 2020; 43(11):2721-2729. DOI: 10.2337/dc19-2267. View

14.

Guyatt G, Oxman A, Vist G, Kunz R, Falck-Ytter Y, Alonso-Coello P . GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336(7650):924-6. PMC: 2335261. DOI: 10.1136/bmj.39489.470347.AD. View

15.

Haidar A, Legault L, Matteau-Pelletier L, Messier V, Dallaire M, Ladouceur M . Outpatient overnight glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or conventional insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2015; 3(8):595-604. DOI: 10.1016/S2213-8587(15)00141-2. View

16.

Nathan D . The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2013; 37(1):9-16. PMC: 3867999. DOI: 10.2337/dc13-2112. View

17.

El-Khatib F, Balliro C, Hillard M, Magyar K, Ekhlaspour L, Sinha M . Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial. Lancet. 2016; 389(10067):369-380. PMC: 5358809. DOI: 10.1016/S0140-6736(16)32567-3. View

18.

Bekiari E, Kitsios K, Thabit H, Tauschmann M, Athanasiadou E, Karagiannis T . Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis. BMJ. 2018; 361:k1310. PMC: 5902803. DOI: 10.1136/bmj.k1310. View

19.

Peters J, Sutton A, Jones D, Abrams K, Rushton L . Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol. 2008; 61(10):991-6. DOI: 10.1016/j.jclinepi.2007.11.010. View

20.

Bakhtiani P, Zhao L, El Youssef J, Castle J, Ward W . A review of artificial pancreas technologies with an emphasis on bi-hormonal therapy. Diabetes Obes Metab. 2013; 15(12):1065-70. PMC: 3766424. DOI: 10.1111/dom.12107. View